UroGen Pharma Ltd.

US$24.75As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:URGNHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR 3.52%
Div yield —
ROE —
Biotechnology
Beta (5Y) 1.64
PE TTM —
TSR TTM 20.91%
Mkt cap US$1.214B
ROIC (45.18%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$29
18.34%
(27.86%)
Hold 5|6|4|3|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.56
0.54
0.58
0.62
5.94%
3.81%
11.74%
15.77%
Revenue$M
114.0
116.6
115.1
114.8
7.06%
6.85%
4.84%
(0.44%)
Peers (US$1.214B)
Cap (US$)
PE
1.227B
—
1.225B
10.77x
1.221B
0.652x
Capital
TTM
5Y
10Y
Leveragex
0.986
(0.296)
(0.299)
EBIT/Intx
0.109
0.191
0.188
Own earn%
114.10
(191.01)
(204.19)
Sh yield%
7.93
17.18
20.25
Owners
Insiders/Inst%
6.66
54.77
Short interest%
3.91
SBC / revenue%
4.10
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
24–29
$1 testx
−0.1
Incr. ROIC%
15